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Abstract
Background: Despite the known efficacy of highly active antiretroviral therapy (HAART), a large
proportion of potentially-eligible HIV-infected patients do not access, and may stand to benefit
from this treatment. In order to quantify these benefits in terms of reductions in hospitalizations
and hospitalization costs, we sought to determine the impact of HAART on hospital readmission
among HIV-infected patients hospitalized at St. Paul's Hospital (SPH) in Vancouver, BC, Canada.
Methods: All patients admitted to a specialized HIV/AIDS ward at SPH (Apr. 1997 – Oct. 2002)
were selected and classified as being on HAART or not on HAART based upon their initial
admission. Patients were then matched by their propensity scores, which were calculated based on
patients' sociodemographics such as age, gender, injection drug use (IDU) status, and AIDS
indication, and followed up for one year. Multivariate logistic regression was used to estimate the
difference in the odds of hospital readmission between patients on and not on HAART.
Results: Out of a total 1084 patients admitted to the HIV/AIDS ward between 1997 and 2002, 662
were matched according to their propensity score; 331 patients each on and not on HAART.
Multivariate logistic regression revealed that patients on HAART had lower odds of AIDS hospital
readmission (OR, 0.61; 95% CI, 0.42 – 0.89) compared to patients not on HAART. Odds of
readmission among patients on HAART were also significantly lower for non-IDU related
readmission (OR, 0.73; 95% CI, 0.53 – 0.99) and overall readmission (OR, 0.72; 95% CI, 0.53 –
0.98).
Conclusion: Propensity score matching allowed us to reliably estimate the association between
exposure (on or not on HAART) and outcome (readmitted to hospital). We found that HIV-
infected patients who were potentially eligible for, but not on HAART had higher odds of being
readmitted to hospital compared to those on HAART. Given the low level of uptake (31%) of
HAART observed in our pre-matched hospitalized cohort, a large potential to achieve clinical
benefits, reduce hospitalization costs and possibly slow disease progression from improved
HAART uptake still exists.
Published: 05 October 2006
BMC Infectious Diseases 2006, 6:146 doi:10.1186/1471-2334-6-146
Received: 05 May 2006
Accepted: 05 October 2006
This article is available from: http://www.biomedcentral.com/1471-2334/6/146
© 2006 Nosyk et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2006, 6:146 http://www.biomedcentral.com/1471-2334/6/146
Page 2 of 6
(page number not for citation purposes)
Background
Despite the known efficacy of highly active antiretroviral
therapy (HAART) and its universal coverage in most prov-
inces in Canada, a sizable proportion of HIV-infected
patients, particularly subgroups of substance users, do not
access HAART [1,2]. Poor uptake, however, is not solely a
Canadian problem; evidence from a large study in Europe
showed that it is not uncommon to find rates of HAART
uptake as low as 59% within observational databases [3],
or as low as 30% among injection drug users (IDUs) [4].
A recent review found that HIV-infected individuals who
fail to access care or who discontinue HAART have the
greatest risk of disease progression and death [5,6].
Uptake and adherence to HAART regimens have also been
shown to reduce hospital resource utilization [7-9]. The
introduction of HAART in Australia was considered to be
the key determinant of a 33% decline in AIDS incidence
between 1995 and 1998 [10]. In addition, a study in the
United States showed that HAART contributed to a 37%
decrease in hospital admissions and a 41% decrease in
hospital days [11].
In response to the high levels of resource utilization and
costs of care for patients with HIV/AIDS, several studies
have focused on identifying predictors of early hospital
readmission (within 14 days). This issue was examined
among HIV-infected patients with bacterial pneumonia
and Pneumocystis Carinii pneumonia. One study prior to
the widespread availability of HAART found leaving hos-
pital alone to be a leading risk factor for early readmis-
sion, citing this as an important indicator of social
isolation [12]. A similar study conducted when HAART
was widely available found that female gender, homeless-
ness, residence in a poor neighbourhood, AIDS diagnosis,
IDU status, leaving hospital against medical advice (AMA)
and previous admission within 6 months was associated
with early readmission [13].
Previous studies based on observational data that com-
pared readmission among different cohorts were subject
to selection bias. In this study, we use a superior study
design by matching our cohorts according to a propensity
score to account for potential differences in characteristics
between patients who were and were not on HAART. We
hypothesized that patients not on HAART would have a
higher probability of readmission within one year.
Methods
Patient population
All patients admitted to the specialized HIV/AIDS ward at
St. Paul's Hospital (SPH), Vancouver, BC, between April
1997 and December 2002 were included in the study.
SPH, located in downtown Vancouver, is a major teaching
hospital of the University of British Columbia, and has
been the main referral center for HIV related diseases since
the epidemic began [14]. The specialized HIV/AIDS ward
provides comprehensive patient care utilizing infectious
disease specialists, nurses, social workers, dietitians,
addiction medicine specialists and community physi-
cians. The study received ethical approval from the Provi-
dence Health Care Research Ethics Board.
Two databases were used for the study: the SPH Health
Records database and the specialized HIV/AIDS ward
database. Hospitalization data, provided by the Health
Records Department at SPH, included patient demo-
graphics, the most responsible diagnosis, IDU status
(injection drug use within past 6 months), living status
(homeless or not), discharge information (any record of
leaving hospital against medical advice (AMA)) and all
hospital resource utilization. The AIDS ward database
added patient histories of AIDS-defining diagnoses (as
listed in table 2), indication of social supports – defined
as whether or not the patient had a partner, family or
friends – and antiretroviral treatment data.
Study design
Each patient's first admission to the HIV/AIDS ward dur-
ing the time period was defined as the index admission, at
which time patients were categorized as being "on HAART
"or "not on HAART". Patients who had ever had an AIDS/
Advanced HIV diagnosis (ICD-9: 42.0–44.9) reported up
to their index admission were classified as having AIDS.
Patients who died at index admission were omitted from
the analysis.
Patients were classified as being readmitted if they were
admitted anywhere within the hospital during one year of
follow-up. To explore the patterns of readmission, the
most responsible diagnosis of readmission was reviewed.
Overall readmission was compared between cohorts,
however the cause some hospital admissions may have
been for reasons other than patients' HIV/AIDS status.
Thus, readmitted patients were further classified in two
additional analyses: 1) being readmitted for AIDS diag-
noses (defined as having been admitted to the AIDS ward
with an AIDS/advanced HIV diagnosis); and 2) being
readmitted for non-IDU reasons if they were ever admit-
ted to the hospital with a most responsible diagnosis not
related to IDU illness during the one-year follow-up. We
chose to examine non-IDU related readmission in order
to separate out the effects of intravenous drug use on hos-
pital resource utilization, which is assumed to be inde-
pendent of any effect that HAART might have. Non-IDU
related admissions include those for AIDS, as well as other
admissions not a result of intravenous drug use.BMC Infectious Diseases 2006, 6:146 http://www.biomedcentral.com/1471-2334/6/146
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Statistical analysis
Univariate comparison between the two cohorts (on
HAART vs. not on HAART) was performed using the Wil-
coxon rank-sum tests for continuous variables and contin-
gency tables for categorical variables.
A propensity score was used to balance baseline character-
istics between the two groups [15,16]. More specifically,
we fitted a logistic regression model to calculate the pro-
pensity score, based on patients' sociodemographics, such
as age, gender, injection drug use (IDU) status, and AIDS
indication. Each patient on HAART was then matched to
the patient not on HAART with the closest propensity
score (up to 5-digit matching).
Multivariate logistic regression models, adjusting for the
propensity score and AMA at index admission, were used
to explore the effects of HAART within the three separate
analyses listed above. The AMA variable was expected to
be associated with hospital readmission, but not with
being on HAART, and was therefore left out of the propen-
sity score match. All statistical analysis was performed
using the SAS 8.2 software program (SAS Institute, Inc.,
Cary, NC).
Results
A total of 1150 patients – 358 (31%) on HAART and 792
(69%) not on HAART – were admitted to the HIV/AIDS
ward between 1997 and 2002. After excluding deaths at
index admission, we had a total of 1084 patients – 342 on
HAART and 742 not on HAART for the analysis. Patient
sociodemographics at index admission are presented in
Table 1. Gender, age, and IDU status were significantly
different between those on and not on HAART. In addi-
tion, homelessness was far more prevalent among sub-
jects not on HAART, as were instances of leaving hospital
against medical advice. Social supports were significantly
greater among those on HAART. The demographics of the
662 matched patients at index admission are shown in the
second set of columns in Table 1. As expected, matched
variables including the proportion of patients with indica-
tion of AIDS, IDU status and homelessness were not sta-
tistically significantly different between those on and not
on HAART.
Table 2 lists all of the previously-indicated AIDS-defining
illnesses of patients in each cohort at index admission pre-
and post-propensity score match. It was shown that before
matching, the proportions of patients who had ever have
CMV, MAC, Lymphoma, Kaposi's sarcoma, and PCP dif-
fered significantly between the two groups. However, the
differences on majority of the illnesses were not statisti-
cally significantly different following the propensity score
matching procedure.
Table 3 lists the results from univariate analysis. The
number of patients readmitted for AIDS diagnoses was
not significantly different between the two groups (76 vs.
95, p = 0.09). Among those without previous indication
of AIDS, patients on HAART were significantly less likely
to be readmitted for AIDS diagnoses than those not on
HAART (3 (2.4%) vs. 18 (14%), p = < 0.01). Also, signifi-
cantly fewer patients on HAART were readmitted for non-
IDU related reasons (141 vs. 168, p = 0.04) and overall
(149 vs. 181, p = 0.01).
Table 4 presents the results from the multivariate logistic
regression models. We found that after adjusting for the
propensity score and AMA indication at index admission,
patients on ART faced lower odds of being readmitted for
AIDS diagnosis (OR 0.66; 95% CI: 0.46 – 0.96), as well as
non-IDU related readmission (OR 0.71; 95% CI: 0.52 –
0.97). Finally, odds of overall readmission were lower
among patients on HAART (OR 0.70; 95% CI: 0.51 –
0.95). Leaving hospital against medical advice (AMA var-
iable) was a significant predictor of readmission overall
(OR: 2.29, 95% CI: 1.31–4.01) for non-IDU related rea-
sons (OR: 2.15, 95% CI: 1.22–3.79), but not for AIDS
diagnoses (OR: 1.38, 95% CI: 0.69–2.78).
Table 1: Patient Demographics: Pre- and Post- Propensity Score Match
Pre-propensity score match Post-propensity score match
On HAART Not on HAART P-value On HAART Not on HAART P-value
Sample size 342 742 331 331
Age (Q1 – Q3) 40.8 (36.3, 46.4) 38.4 (33.3, 44.6) < 0.01 40.8 (36.1, 46.2) 40.8 (35.8, 47.3) 0.68
Female (%) 43 (12.6) 194 (26.2) < 0.01 43 (13.0) 39 (11.8) 0.64
Social support (%) 255 (74.6) 489 (66.0) < 0.01 246 (74.3) 242 (73.1) 0.74
Homeless (%) 6 (1.8) 67 (9.0) < 0.01 6 (1.8) 6 (1.8) 0.52
AIDS (%) 207 (60.5) 458 (61.7) 0.71 205 (61.9) 202 (61.0) 0.81
IDU (%) 85 (24.9) 357 (48.1) < 0.01 85 (25.7) 82 (24.8) 0.79
AMA (%) 26 (7.6) 132 (17.8) < 0.01 26 (7.9) 43 (13.0) 0.03
IDU = Intravenous Drug Use, AMA = Indicates leaving hospital against medical advice.BMC Infectious Diseases 2006, 6:146 http://www.biomedcentral.com/1471-2334/6/146
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Discussion
In this study, we applied propensity score methodology to
investigate the impact of HAART on hospital readmission.
Our results showed that HAART reduces the odds of hos-
pital readmission, primarily for diagnoses of HIV-related
illness, including AIDS-defining diagnoses. The advan-
tages of using propensity score matching in observational
epidemiological studies have been addressed elsewhere
[20]. Generally speaking, treated and non-treated cohorts
in observational studies may differ on a number of base-
line covariates; ignoring these differences may confound
the treatment effect, thus biasing estimates of treatment
effect. The propensity score method allowed us reduce
selection bias by minimizing differences in patients'
observed covariates in the comparison of those on and
not on treatment and therefore provided more reliable
estimates of treatment effect.
Controlling for AIDS indication, gender and IDU status,
which are supported within the literature as univariate
predictors of being treated with HAART [18-20], patients
on HAART had significantly lower odds of being readmit-
ted to hospital for AIDS diagnoses. This result was found
regardless of the fact that patients on HAART had (margin-
ally) more AIDS diagnoses at index admission, suggesting
that this cohort was slightly sicker, and would require
more hospitalizations. Further analysis using Cox regres-
sion showed that, controlling for leaving hospital AMA,
time to readmission was found to be statistically signifi-
cantly shorter among those not on HAART (results not
presented). Our results are conservative, given the possi-
bility that some patients may have taken up, or dropped
out of treatment in the 'not on HAART' and 'on HAART'
cohorts, respectively. Furthermore, we found that patients
who had not previously been diagnosed with AIDS and
were not on HAART were significantly more likely to be
readmitted for an AIDS diagnosis than those not previ-
ously diagnosed with AIDS who were on HAART. This
result suggests more rapid disease progression among
patients not on HAART during our one-year follow-up
period; a result also supported by existing literature [6].
We found that a relatively high proportion of patients in
each group were readmitted to hospital after index admis-
sion (on HAART = 42%, not on HAART = 51%). This is
high in comparison to Sherer et al., who found that only
Table 3: Readmissions in the One-Year Follow-Up Period
On HAART N (%) Not on HAART N (%) P-value
Sample size 331 331
Readmitted for AIDS diagnosis 76 (23.0) 95 (28.7) 0.09
With previous AIDS indication1 73 (35.6) 77 (38.1) 0.60
Without previous AIDS indication2 3 (2.4) 18 (14.0) < 0.01
Readmitted for non-IDU related reasons 141 (42.6) 168 (50.8) 0.04
Overall readmitted 149 (45.0) 181 (54.7) 0.01
1. On HAART: n = 205, not on HAART: n = 202.
2. On HAART: n = 126, not on HAART: n = 129.
Table 2: AIDS-Defining Illnesses at Index Admission: Pre- and Post- Propensity Score Match
Pre-Propensity Score Match Post-Propensity Score Match
On HAART N (%) Not on HAART N (%) P-value On HAART N (%) Not on HAART N (%) P-value
CMV 27 (7.9) 15 (2.0) < 0.01 27 (8.2) 8 (2.4) < 0.01
Candidiasis 23 (6.7) 35 (4.7) 0.17 23 (7.0) 17 (5.1) 0.33
Cryptococcis 10 (2.9) 31 (4.2) 0.31 10 (3.0) 14 (4.2) 0.41
HIV Dementia 12 (3.5) 16 (2.2) 0.19 12 (3.6) 15 (4.5) 0.56
Kaposi's Sarcoma 30 (8.8) 24 (3.2) < 0.01 30 (9.1) 17 (5.1) 0.05
Lymphoma 17 (5.0) 20 (2.7) 0.06 17 (5.1) 14 (4.2) 0.58
MAC 29 (8.5) 28 (3.8) < 0.01 29 (8.8) 12 (3.6) 0.87
PCP 84 (24.6) 135 (18.2) 0.02 83 (25.1) 68 (20.1) 0.85
Pneumonia 29 (8.5) 83 (11.2) 0.17 29 (8.8) 30 (9.1) 0.89
Toxoplasmosis 6 (1.8) 8 (1.1) 0.36 6 (1.8) 3 (0.9) 0.78
Tuberculosis 8 (2.3) 27 (3.6) 0.26 8 (2.4) 10 (3.0) 0.79
Wasting 24 (7.0) 36 (4.9) 0.15 24 (7.3) 19 (5.7) 0.66
CMV = Cytomegalovirus, MAC = Mycobacterium Avium Complex, PCP = Pneumocystis Carinii Pneumonia.BMC Infectious Diseases 2006, 6:146 http://www.biomedcentral.com/1471-2334/6/146
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25% of a patient population that had visited an urban
public hospital HIV clinic was hospitalized in a given year
[21]. The possible explanation for the difference is that
our study population may be at a more advanced disease
stage, as our cohort included high proportion of patients
with AIDS and the cohort was followed after an inpatient
visit, rather than outpatient visit which was indicated in
Sherer et al. study. In addition, under Canadian health-
care system, inpatient care was free of charge, which may
differ from studies conducted in different healthcare set-
tings. Publicly funded health system might induce
patients to use more health care resources, including visit-
ing hospital more often. As a result, the probability of
being admitted might be higher than those under other
healthcare settings.
Our analysis also highlighted the fact that an alarming
proportion of HIV-infected patients admitted to hospital
were not being treated with HAART. Only 31% of patients
admitted to the specialized AIDS ward from 1997–2002
were on HAART. Low rates of uptake were also observed
in a cohort of ICU-presenting HIV/AIDS patients in Italy
[22]. This recent study found that hospitalization patterns
before and after the introduction of HAART had not
changed, primarily due to a flat rate of ART uptake
between 1994 and 1998. Physician discretion [23], dis-
continuation due to drug toxicity or intolerance [24,25]
and patient attitudes against the efficacy of antiretroviral
therapy [16,26-28] have all been indicated as reasons why
patients may not choose HAART.
The following limitations merit discussion. First, CD4
count at index admission was not controlled for in the
baseline analysis. The causal relationship between CD4
and HAART initiation is unclear and time of HAART initi-
ation in our population is unknown. In addition, the
objective of HAART therapy is to increase CD4 count, and
thus reduce the onset of AIDS-defining illnesses and other
disease which require inpatient care. CD4 count is there-
fore an intermediate variable in the causal pathway
between the exposure (HAART) and outcome (hospital
readmission); inclusion of this covariate would constitute
one type of overmatching, which is to be avoided [29].
Second, although we only observed inpatient care at a sin-
gle institution, given its central geographical location and
the comprehensive and specialized care available for this
population at SPH, it is unlikely that our patient popula-
tion sought care elsewhere in the follow-up period.
Finally, treatment history, disease duration and the rea-
sons patients were not on HAART were unknown. We
believe that the use of the propensity score method to
control for the existence of imbalanced covariates
between our case and control cohorts provided us with
the most unbiased estimates of treatment effect possible
and limited the impact of the omission of these variables.
Conclusion
HIV-infected patients who were not on HAART were read-
mitted to hospital more frequently and therefore utilized
more hospital resources overall compared to those on
HAART. The implications of these results are important to
both physicians and health care administrators. From the
physician's perspective, low uptake and the evidence of its
consequences on disease progression in a matched cohort
of patients highlights the need for healthcare providers to
engage eligible HIV-infected persons in a frank discussion
addressing the barriers to HAART that many patients face.
From an administrative perspective, although antiretrovi-
Table 4: Results from Multivariate Logistic Regression Models
Multivariate Logistic Regression On HAART vs. Not on HAART AMA vs. Not AMA
Odds Ratio (95%C.I.) Odds Ratio (95%C.I.)
AIDS readmission1
Not Readmitted 1 1
Readmitted for AIDS-related illness 0.66 (0.46, 0.96) 1.38 (0.69, 2.78)
Readmitted for other reasons 0.74 (0.50, 1.10) 3.39 (1.84, 6.24)
Non-IDU related readmission1
Not Readmitted 1 1
Readmitted for non-IDU related reasons 0.71 (0.52, 0.97) 2.15 (1.22, 3.79)
Readmitted for IDU-related reasons 0.54 (0.21, 1.37) 4.02 (1.37, 11.86)
Overall readmission
Not Readmitted 1 1
Readmitted 0.70 (0.51, 0.95) 2.29 (1.31, 4.01)
1. Multinomial, multivariate logistic regression.BMC Infectious Diseases 2006, 6:146 http://www.biomedcentral.com/1471-2334/6/146
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ral drug costs may be considerable, our study provides
some evidence that these costs will be offset by decreased
hospitalization costs.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BN took part in the conception of the study design and
interpretation of results and drafted the manuscript, HS
undertook statistical analyses and took part in conceiving
the study design and interpreting results, XL took part in
conceiving the study design and interpreting results, AP
was involved in the critical revision of the article for
important intellectual content, AA was involved in the
critical revision of the article for important intellectual
content. All authors read and approved the final manu-
script.
Acknowledgements
This was an unfunded study conducted by the Canadian HIV Trials Net-
work. Bohdan Nosyk is supported by doctoral research fellowships from 
the Canadian Institutes of Health Research, the Michael Smith Foundation 
of Health Research, and the Research in Addictions and Mental Health Pol-
icy & Services (RAMHPS) CIHR-strategic training initiative. Dr. Xin Li holds 
a Michael Smith Foundation for Health Research Postdoctoral Fellowship. 
The authors would like to acknowledge Barbara Vinduska and Sonia Sizto 
for their work in managing the database, and Dianne Calbick's administra-
tive assistance.
References
1. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH: Uptake and
adherence to highly active antiretroviral  therapy among
HIV-infected people with alcohol and other substance use
problems: the impact of substance abuse treatment.  Addiction
2004, 99(3):361-8.
2. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV,
Montaner JS, Schechter MT, Hogg RS: Barriers to use of free
antiretroviral therapy in injection drug users.  JAMA 1998,
280:547-9.
3. CASCADE Collaboration: Changes in the uptake of antiretrovi-
ral therapy and survival in people with known duration of
HIV infection in Europe: results from CASCADE.  HIV Medi-
cine 2000, 1:224-31.
4. Muga R, Egea JM, Sanvisens A, Arnal J, Tural C, Tor J, Rey-Joly C:
Impact of injecting drug use on the interruption of antiretro-
viral therapies.  J Epidemiol Community Health 2004, 58:286-7.
5. Lucas GM, Chaisson RE, Moore RD: Survival in an urban HIV-1
clinic in the era of highly active antiretroviral therapy: a 5-
year cohort study.  Journal of Acquired Immune Deficiency Syndromes
2003, 33:321-8.
6. Lucas GM: Antiretroviral adherence, drug resistance, viral fit-
ness and HIV disease progression: a tangled web is woven.
Journal of Antimicrobial Chemotherapy . 2005; Feb 18.
7. Sendi PP, Bucher HC, Harr T, Craig BA, Schweitert M, Pfluger D,
Gafni A, Battegay M: Cost-effectiveness of highly active antiret-
roviral therapy in HIV-infected patients.  Swiss HIV Cohort Study
AIDS 1999, 13(9):1115-22.
8. Miners AH, Sabin CA, Trueman P, Youle M, Mocroft A, Johnson M,
Beck EJ: Assessing the cost-effectiveness of highly active
antiretroviral therapy for adults with HIV in England.  HIV
Medicine 2001, 2:52-8.
9. Holmes WC: HIV/AIDS, utilities, and cost-effectiveness analy-
sis: stepping toward the future.  Med Decis Making 2002,
22(6):522-5.
10. Law MG, Li Y, McDonald AM, Cooper DA, Kaldor JM: Estimating
the population impact in Australia of improved antiretrovi-
ral treatment for HIV infection.  AIDS 2000, 14:197-201.
11. Moore R: HIV Therapy and prevention: economics and cost-
effectiveness.  Hopkins HIV Rep 1998, 10(5):10-1.
12. Grant RW, Charlebois ED, Wachter RM: Risk factors for early
hospital readmission in patients with AIDS and pneumonia.
J Gen Intern Med 1999, 14:531-6.
13. Palepu A, Sun H, Kuyper L, Schechter MT, O'Shaughnessy MV, Anis
AH: Early hospital readmission in HIV-infected patients.  J Gen
Intern med 2003, 18:242-7.
14. Goldberg M, Graves J: The Greater Vancouver Regional Dis-
trict: On our streets and in our shelters: Results of the 2005
Greater Vancouver Homeless Count.  2005 [http://
www.gvrd.bc.ca/homelessness/research.htm].
15. D'Agostino RB: Propensity score methods for bias reduction in
the comparison of a treatment to a non-randomized control
group.  Statist Med 1998, 17:2265-81.
16. Elad Y, French WJ, Shavelle DM, Parsons LS, Sada MJ, Every NR: Pri-
mary angioplasty and selection bias in patients presenting
late (> 12 h) after onset of chest pain and ST elevation myo-
cardial infarction.  Journal of the American College of Cardiology 2002,
39(5):826-33.
17. Joffe MM, Rosenbaum PR: Invited Commentary: Propensity
Scores.  American Journal of Epidemiology 1999, 150(4):327-3.
18. Ezzy DM, Bartos MR, O de Visser R, Rosenthal DA: Antiretroviral
uptake in Australia: medical, attitudinal and cultural corre-
lates.  International Journal of STD and AIDS 1998, 9:579-86.
19. Palepu A, Yip B, Miller C, Strathdee SA, O'Shaughnessy MV, Montaner
JSG, Hogg RS: Factors associated with the response to antiret-
roviral therapy among HIV-infected patients with and with-
out a history of injection drug use.  AIDS 2001, 15(3):423-4.
20. Turner BJ, Laine C, Cosler L, Hauck WW: Health care delivery
with Antiretroviral adherence.  J Gen Intern Med 2003,
18:248-57.
21. Sherer R, Pulvirenti J, Stieglitz K, Narra J, Jasek J, Green L, Moore B,
Shott S, Cohen M: Hospitalization in HIV in Chicago.  J Int Assoc
Physicians AIDS Care (Chic Ill) Winter 2002, 1(1):26-33.
22. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B:
Impact of HAART advent on admission patterns and survival
in HIV-infected patients admitted to an intensive care unit.
AIDS 2004, 18:1429-33.
23. Bangsberg D, Tulsky JP, Hecht RM, Moss AR: Protease Inhibitors
in the Homeless.  JAMA 1997, 278:63-65.
24. Bini T, Testa L, Chiesa E, et al.: Outcome of a second-line pro-
tease inhibitor-containing regimen in patients failing or
intolerant of a first highly active antiretroviral therapy.  JAIDS
2000, 24:115-22.
25. Park-Wyllie LY, Scalera A, Tseng A, Rourke S: High rate of discon-
tinuations of highly active antiretroviral therapy as a result
of antiretroviral intolerance in clinical practice: missed
opportunities for adherence support?  AIDS 2002, 16(7):1084-6.
26. Richter R, Micheals M, Carlson B, Coates T: Motivators and Barri-
ers to Use of Combination Therapies in Patients with HIV
Disease.  In San Francisco: Centre for AIDS Prevention Studies University
of California; 1998. 
27. Catt S, Stygal J, Catalan J: Acceptance of Zidovudine (AZT) in
early HIV disease: the role of health benefits.  AIDS Care 1995,
7:229-35.
28. Mossar M, Lefevre F, Deutsche J, Wesch J, Glassroth J: Factors pre-
dicting compliance with prophylactic treatments among
HIV positive patients.  Int Conf AIDS 1993, 9(2):787. (abstract no.
PO-D01-3418).
29. Rothman KJ, Greenland S: Modern Epidemiology.  2nd edition.
Lippincott-Raven Publishers Philadelphia; 1998:155-7. 
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/6/146/pre
pub